Los Angeles, California headquartered Puma Biotechnology Inc.'s stock finished Thursday's session 3.65% lower at $33.00 with a total trading volume of 850,187 shares. The Company's shares have advanced 7.49% on an YTD basis. The stock is trading 15.73% below its 50-day moving average. Additionally, shares of Puma Biotechnology, which focuses on the development and commercialization of products for the treatment of various forms of cancer, have a Relative Strength Index (RSI) of 45.09.
On December 19th, 2016, Puma Biotechnology announced that it will voluntarily move its stock exchange listing from the NYSE to the NASDAQ exchange. Puma's common stock will be traded on the Nasdaq Global Select Market, which is for public companies that meet the highest standards with measures including market value and liquidity. The Company's common stock will continue to trade under the ticker symbol "PBYI." The free research report on PBYI is available at:
On Thursday, shares in Bothell, Washington headquartered Seattle Genetics Inc. recorded a trading volume of 3.23 million shares, which was above their three months average volume of 1.34 million shares. The stock ended the session 0.62% lower at $54.87. The Company's shares have advanced 3.98% since the start of this year. The stock is trading 14.22% above its 200-day moving average. Moreover, shares of Seattle Genetics, which develops and commercializes targeted therapies for the treatment of cancer worldwide, have an RSI of 40.41.
On December 12th, 2016, research firm Credit Suisse downgraded the Company's stock rating from 'Outperform' to 'Neutral'.
On January 05th, 2017, Seattle Genetics announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma (MM). SGN-CD352A is an investigational CD352-targeted antibody-drug conjugate (ADC) utilizing Seattle Genetics' proprietary ADC technology, an engineered cysteine antibody (EC-mAb) stably linked to a highly potent cytotoxic agent called a pyrrolobenzodiazepine dimer. The trial is designed to assess the safety and antitumor activity of SGN-CD352A. This study represents Seattle Genetics' first clinical-stage ADC program in development for MM, demonstrating the breadth of potential therapeutic applications for its industry-leading ADC technology platform. The complimentary report on SGEN can be downloaded at:
Shares in Princeton, New Jersey-based Advaxis Inc. closed the day 0.76% lower at $7.88 with a total trading volume of 512,989 shares. The stock has gained 10.06% on an YTD basis. The Company's shares are trading 8.54% below their 50-day moving average. Additionally, shares of Advaxis, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have an RSI of 48.36.
As per a SEC filing dated December 15th, 2016, Advaxis announced that Gregory T. Mayes, Executive Vice President and Chief Business Officer, has resigned from the Company in order to pursue a business opportunity focused on the development of a treatment for epileptic seizures. The resignation will be effective as of December 30th, 2016. The Company also announced the promotion of Sara Bonstein, the Company's Chief Financial Officer, to Executive Vice President, effective as of December 30th, 2016. Visit us today and download our complete research report on ADXS for free at:
At the close, shares in Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc. finished 0.73% higher at $6.93. The stock recorded a trading volume of 994,865 shares, which was above its three months average volume of 862,450 shares. The Company's shares have gained 26.23% in the last one month, 50.65% over the previous three months, and 9.48% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 25.49% and 70.12%, respectively. Furthermore, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have an RSI of 66.81.
On November 07th, 2016, BioCryst Pharmaceuticals reported that Q3 2016, revenues decreased to $7.8 million from $11.0 million in Q3 2015. The Company's net loss for Q3 2016 was $11.5 million, or a $0.16 net loss per share compared to a net loss of $14.6 million, or $0.20 net loss per share, for Q3 2015. Get free access to your technical report on BCRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA